Process of making a crystalline EDG-2 receptor antagonist

A process for the preparation of a Crystalline Form 1 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I):

• the process comprising the steps of:
• (1) adding a mixture comprising a compound of Formula 2:
• wherein M is Na+, K+, or Li+;
• in a solvent onto a slurry of citric acid;
• and
• (2) isolating Crystalline Form 1 Compound I by filtration;
• wherein Crystalline Form 1 of Compound I is characterized as having:
• an X-ray powder diffraction (XRPD) pattern with peaks at 5.2±0.2° 2-Theta, 9.0±0.2° 2-Theta, 14.4±0.2° 2-Theta, and 17.7±0.2° 2-Theta, as measured using Cu (Ka) radiation.